Philip Ward

Expert outlines approaches to preventing fraud in clinical research-a more prevalent problem that many believe.

Vienna joins growing list of bidders to land Europe's drug regulator; Amsterdam the early favorite?

Pressure is growing on clinical trial organizers to involve more pregnant women in drug research.

European experts in postmarking safety surveillance have the most to loose from impending EMA move post-Brexit.

In an open letter issued this week, the heads of research and development from several big pharma companies and the EFPIA have demanded a quick decision on the relocation of the EMA.

The EMA has unveiled a new survey to assess how its communication strategy to the general public is perceived and valued by its stakeholders.

The Regulatory Affairs Professionals Society (RAPS) is seeking to increase its presence in Europe and expanding its European team.

The global skills shortage in the clinical research sector is being exacerbated in the U.K. by the uncertainty created by Brexit.

Synexus and Radiant Research are merging their operations to form a single global site network of 185 sites with 1,500 employees.

The European Medicines Agency (EMA) has developed a three-year plan to formalize, structure and develop interactions with the academic community.

The European Forum for Good Clinical Practice to examine the impact of current regulations and areas such as big data and quality management on so-called complex studies.

Women are often underrepresented in HIV clinical trials, but they appear to prefer finding out about trials by means of peer-to-peer communication, according to new analysis.

An emergency summit to discuss how to safeguard the clinical research industry in the U.K. before and after Brexit will take place on April 5.

Regulators in the European Union (EU) and the U.S. have agreed to recognize inspections of manufacturing sites for human medicines conducted in their respective territories on both sides of the Atlantic.

The EFPIA has revealed the appointment of Nathalie Moll as its new director general.